Persistent excess mortality in post-pandemic Japan: current evidence, methodological limitations, and future directions.

Publication date: May 11, 2026

More than six years after the emergence of COVID-19, Japan continues to experience persistently elevated excess mortality despite entering a post-pandemic phase. Excess mortality, defined as the difference between observed and expected deaths, reflects both direct and indirect effects of the pandemic, including healthcare disruption, delayed care, and broader social changes. In Japan, mortality decreased slightly in 2020 but increased markedly from 2022 onward, with annual excess deaths approaching 100,000, despite widespread vaccination and the predominance of the less virulent Omicron variant. Multiple factors may underlie this sustained increase, including population aging, changes in healthcare access, delayed diagnosis and treatment, regional disparities, and psychosocial stress. Some ecological and observational studies have reported a statistical association between repeated COVID-19 booster vaccination and excess mortality in Japan; however, these findings do not establish causality, and a causal relationship cannot currently be concluded. Against this background, this narrative review examines persistent excess mortality in Japan, uses the literature on repeated booster vaccination as an illustrative example to highlight methodological limitations, and discusses the need for nationwide, linked individual-level data infrastructure and appropriate analytical frameworks for more robust future evaluations.

Open Access PDF

Concepts Keywords
Annual all-cause mortality
Japan booster vaccination
Mortality COVID-19
Vaccination COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
excess mortality
healthy vaccinee bias
Humans
Immunization, Secondary
individual-level data infrastructure
Japan
methodological limitations
Mortality
Pandemics
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME Reproduction
disease MESH fac
disease MESH infection
disease MESH death
disease MESH included
disease MESH dis
drug DRUGBANK Fenamole
disease MESH influenza
drug DRUGBANK Flunarizine
disease MESH mul
disease MESH herpes zoster
disease MESH tinnitus
disease MESH myocarditis
disease MESH pericarditis
disease MESH syndrome
disease MESH sudden cardiac death
disease MESH pulmonary embolism
disease MESH cancer
drug DRUGBANK Coenzyme M
disease MESH respiratory infections
disease MESH Abers
disease MESH emergency
disease MESH bed
disease MESH sudden death
disease MESH pancreatic cancer
pathway KEGG Pancreatic cancer
disease MESH injury
disease MESH plan

Original Article

(Visited 73 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *